<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36257950</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.</ArticleTitle><Pagination><StartPage>6152</StartPage><MedlinePgn>6152</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-33825-5</ELocationID><Abstract><AbstractText>We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p&#x2009;&gt;&#x2009;0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nevalainen</LastName><ForeName>Olli P O</ForeName><Initials>OPO</Initials><Identifier Source="ORCID">0000-0002-5665-229X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hatanp&#xe4;&#xe4; Health Center, City of Tampere, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pirkanmaa Hospital District, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horstia</LastName><ForeName>Saana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laakkonen</LastName><ForeName>Sanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutanen</LastName><ForeName>Jarno</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustonen</LastName><ForeName>Jussi M J</ForeName><Initials>JMJ</Initials><AffiliationInfo><Affiliation>Occupational Health Helsinki, City of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalliala</LastName><ForeName>Ilkka E J</ForeName><Initials>IEJ</Initials><Identifier Source="ORCID">0000-0002-7664-0587</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, Helsinki University and University Hospital Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansakorpi</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreivi</LastName><ForeName>Hanna-Riikka</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0002-9361-8322</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuutti</LastName><ForeName>Pauliina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Juuso</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4364-2201</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkkila</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University and Fimlab Ltd., Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paukkeri</LastName><ForeName>Erja-Leena</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perola</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Welfare, Population Health Unit, Public Health Research Team, Finnish Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourjamal</LastName><ForeName>Negar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1430-3075</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1414-5433</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosberg</LastName><ForeName>Tuomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Kanta-H&#xe4;me Central Hospital, H&#xe4;meenlinna, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutanen</LastName><ForeName>Taija</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Suomen Covid -yhdistys ry, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savolainen</LastName><ForeName>Joni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Suomen Covid -yhdistys ry, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Solidarity Finland Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Haukka</LastName><ForeName>Jari K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0003-1450-6208</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinicum/Department of Public Health, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyatt</LastName><ForeName>Gordon H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tikkinen</LastName><ForeName>Kari A O</ForeName><Initials>KAO</Initials><Identifier Source="ORCID">0000-0002-1389-8214</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. kari.tikkinen@helsinki.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland. kari.tikkinen@helsinki.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>H.-R.K. served on advisory boards for Roche, and Pfizer outside the submitted work. T.R. reported honoraria from AstraZeneca, Boehringer-Ingelheim, and GSK outside the submitted work; and reported having support for attending meetings from MSD, Roche, and Orion outside the submitted work. The remaining authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Ala-Kokko</LastName><ForeName>Tero</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonen</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delany</LastName><ForeName>Jutta</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ekroos</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hankkio</LastName><ForeName>Riina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haukip&#xe4;&#xe4;</LastName><ForeName>Mia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hetem&#xe4;ki</LastName><ForeName>Iivo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holma</LastName><ForeName>Pia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmberg</LastName><ForeName>Ville</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jalkanen</LastName><ForeName>Ville</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouppila</LastName><ForeName>Jenni</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;ms&#xe4;nen</LastName><ForeName>Toni</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;rventie</LastName><ForeName>Juuso</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;rvinen</LastName><ForeName>Petrus</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauma</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilpel&#xe4;inen</LastName><ForeName>Tuomas P</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komulainen</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuitunen</LastName><ForeName>Ilari</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamminm&#xe4;ki</LastName><ForeName>Satu M H</ForeName><Initials>SMH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattila</LastName><ForeName>Tiina M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myll&#xe4;rniemi</LastName><ForeName>Marjukka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;kinen</LastName><ForeName>Laura K</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;ntyl&#xe4;</LastName><ForeName>Jarkko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;&#xe4;tt&#xe4;</LastName><ForeName>Gitte</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niskanen</LastName><ForeName>Joni</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyk&#xe4;nen</LastName><ForeName>Taina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyqvist</LastName><ForeName>Miro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Partanen</LastName><ForeName>Terhi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patovirta</LastName><ForeName>Riitta-Liisa</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puusti</LastName><ForeName>Emmi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reponen</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Risku</LastName><ForeName>Sari</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saalasti</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salonen</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinisalo</LastName><ForeName>Marjatta U</ForeName><Initials>MU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sivenius</LastName><ForeName>Katariina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xe4;il&#xe4;</LastName><ForeName>Petrus</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuominen</LastName><ForeName>Susanna</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36257950</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-33825-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. World Health Organization https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2022).</Citation></Reference><Reference><Citation>Munblit D, et al. Long COVID: aiming for a consensus. Lancet Respir. Med. 2022;S2213-2600:00135&#x2013;00137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067938</ArticleId><ArticleId IdType="pubmed">35525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114:865&#x2013;871. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Can drugs reduce the risk of long COVID? What scientists know so far. Nature. 2022;604:20&#x2013;21. doi: 10.1038/d41586-022-00823-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00823-y</ArticleId><ArticleId IdType="pubmed">35338366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutanen J, et al. Remdesivir in the treatment of hospitalized patients with COVID-19: Solidarity Finland, a pragmatic, adaptive, randomized multicentre study. Finn. Med. J. 2022;77:e32811.</Citation></Reference><Reference><Citation>Tikkinen KAO, Malekzadeh R, Schlegel M, Rutanen J, Glasziou P. COVID-19 clinical trials: learning from exceptions in the research chaos. Nat. Med. 2020;26:1671&#x2013;1672. doi: 10.1038/s41591-020-1077-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1077-z</ArticleId><ArticleId IdType="pubmed">32963376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, et al. Outpatient remdesivir to prevent progression to severe covid-19. N. Engl. J. Med. 2022;386:1094. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pubmed">35172053</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 10.1016/s0140-6736(22)00519-0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060606</ArticleId><ArticleId IdType="pubmed">35512728</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasziou PP, Tikkinen KAO. The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic. J. R. Soc. Med. 2021;114:443&#x2013;446. doi: 10.1177/01410768211041245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211041245</ArticleId><ArticleId IdType="pmc">PMC8451011</ArticleId><ArticleId IdType="pubmed">34533083</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, C. C., et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial (October 4, 2022). Available at SSRN: https://ssrn.com/abstract=4237902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19&#x2014;interim WHO Solidarity trial results. N. Engl. J. Med. 2021;384:497. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>